Table 2

Impact of ever versus never regressing to NGR in DPP on microvascular outcomes in DPPOS

OR95% CIP
Lower limitUpper limit
Aggregate MVD
 Adjustment covariates
  Model 1: univariate (unadjusted)0.7040.5880.843<0.001
  Model 2: adjusted for age, sex, race/ethnicity, baseline A1C0.7650.6350.9220.005
  Model 3: model 2 adjustments + treatment group0.7840.6490.9470.011
  Model 4: model 3 adjustments + average A1C during follow-up0.9530.7831.1600.629
  Model 5: model 3 adjustments + diabetes status at end of follow-up0.9160.7501.1210.395
Nephropathy
 Adjustment covariates
  Model 1: univariate (unadjusted)0.6380.5000.813<0.001
  Model 2: adjusted for age, sex, race/ethnicity, baseline A1C0.6950.5420.8920.004
  Model 3: model 2 adjustments + treatment group0.6890.5350.8880.004
  Model 4: model 3 adjustments + average A1C during follow-up0.8080.6231.0490.109
  Model 5: model 3 adjustments + diabetes status at end of follow-up0.8870.6781.1610.384
Retinopathy
 Adjustment covariates
  Model 1: univariate (unadjusted)0.6600.5000.8800.004
  Model 2: adjusted for age, sex, race/ethnicity, baseline A1C0.6750.5080.8980.007
  Model 3: model 2 adjustments + treatment group0.6720.5040.8970.007
  Model 4: model 3 adjustments + average A1C during follow-up0.8500.6301.1470.288
  Model 5: model 3 adjustments + diabetes status at end of follow-up0.7380.5441.0010.051
Neuropathy
 Adjustment covariates
  Model 1: univariate (unadjusted)0.8100.6101.0700.131
  Model 2: adjusted for age, sex, race/ethnicity, baseline A1C0.9500.7001.2800.738
  Model 3: model 2 adjustments + treatment group1.0240.7541.3920.878
  Model 4: model 3 adjustments + average A1C during follow-up1.1440.8341.5710.404
  Model 5: model 3 adjustments + diabetes status at end of follow-up1.0550.7611.4640.747